Pharmacquired: Is $11B enough to secure Sanofi's spot in hemophilia?

Pharmacquired: Is $11B enough to secure Sanofi's spot in hemophilia?

Source: 
Biopharma Dive
snippet: 

Gene therapies and other long-acting treatments are threatening to outdate the drugs Sanofi got from its Bioverativ deal.